Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 5/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | AKT1 | P31749 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.51 |
| ▸ | MYLK4 | Q86YV6 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977986 | 0.95 | AKT2 (0.59) | AKT2HTR2AHRH1AKT1TDP1 | |
| SCHEMBL1977716 | 0.89 | AKT2 (0.68) | AKT2AKT1ROCK1ROCK2 | |
| SCHEMBL3014462 | 0.87 | AKT2 (0.51) | AKT2HTR2AHRH1AKT1TDP1 | |
| SCHEMBL3019496 | 0.87 | AKT2 (0.54) | AKT2HTR2AHRH1AKT1ROCK1 | |
| SCHEMBL3029915 | 0.80 | AKT2 (0.47) | AKT2AKT1ROCK1ROCK2 | |
| SCHEMBL1978044 | 0.80 | AKT2 (1.00) | AKT2HTR2AAKT1ROCK1ROCK2 | |
| SCHEMBL13114026 | 0.80 | AKT2 (0.67) | AKT2AKT1ROCK1ROCK2MYLK4 | |
| SCHEMBL1978482 | 0.79 | CHRM2 (0.67) | AKT2HTR2AHRH1ROCK1ROCK2 | |
| SCHEMBL3031739 | 0.79 | AKT2 (0.44) | AKT2ROCK1ROCK2 | |
| SCHEMBL3026285 | 0.77 | AKT2 (0.52) | AKT2HTR2AHRH1AKT1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | claimed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | claimed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | claimed |
| US-8541461-B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2013-09-24 | — | — | US | claimed |
| US-20130005702-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-01-03 | — | — | US | claimed |
| US-8343953-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-01-01 | — | — | US | claimed |
| US-8247576-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-21 | — | — | US | claimed |
| CN-1922148-B | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LTD | 2012-03-21 | — | — | CN | claimed |
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-16 | — | — | US | claimed |
| EP-1706385-B1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2010-10-06 | — | — | EP | claimed |
| EP-2228369-A1 | Pyrazole derivatives as protein kinase modulators | Astex Therapeutics Ltd. (GB) | 2010-09-15 | — | — | EP | claimed |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-01 | — | — | US | claimed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | claimed |
| EP-1933832-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2008-06-25 | — | — | EP | claimed |
| EP-1902032-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-03-26 | — | — | EP | claimed |
| CN-1922148-A | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2007-02-28 | — | — | CN | claimed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | claimed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 124/4885HTR2A 907/4885HRH1 1136/4885 |
| US-20130005702-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | PRKCB, MAP3K19, MAP4K2 | AKT2 146/4885HTR2A 3715/4885HRH1 4137/4885 |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 114/4885HTR2A 862/4885HRH1 1024/4885 |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, GRK2 | AKT2 37/4885HTR2A 554/4885HRH1 826/4885 |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, ERBB3, NCOA3 | AKT2 214/4885HTR2A 899/4885HRH1 977/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 114/4885HTR2A 862/4885HRH1 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.